甲状旁腺功能亢进症增加慢性肾脏病患者心血管疾病风险的研究进展

The research on hyperparathyroidism increase the risk of cardiovascular disease in chronic kidney disease

继发性甲状旁腺功能亢进症(SHPT)是慢性肾脏病(CKD)的一个早期并发症。过度升高的甲状旁腺激素(PTH)可促使CKD患者心肌肥厚,心肌、瓣膜及血管钙化,导致心律失常及心功能异常,甚至会影响血脂及血压,是心血管事件死亡率增加的一个重要的因素。目前,主要有使用饮食控制、含磷螯合剂、维生素D及其衍生物和手术等多种治疗方法。此外,Velcalcetide(AMG 416),一种最新发现的长效钙敏感受体激动剂,在有效治疗继发性甲状旁腺功能亢进症的新型药物方面显示了广阔的前景。

Secondary hyperparathyroidism （SHPT） is an early complication in chronic kidney disease （CKD）. The excessively elevated PTH in patients with CKD may promote cardiac hypertrophy, myocardial, valvular and vascular calcification, lead to arrhythmias and cardiac dysfunction, and what＇s more, even affect blood lipids and blood pressure, causing it to be a key factor that leads to the mortality increase of cardiovascular events. Currently, the treatments of SHPT mainly include diet control, phosphorus chelating agents, vitamin D and its derivatives, surgery and so on. In addition, Velcalcetide （AMG 416）, a novel peptide agonist of the calcium sensing receptor （CaSR）, has broad application prospects of new drugs in the effective treatment of secondary hyperoarathyroidism.